Mirror Daily

Thursday, January 28, 2021
Log in
  • Home
  • National & Global News
  • Business & Economy
  • Tech & Science
  • Health
  • About Mirror Daily
    • Our Team
    • Contact Us
    • Terms of Use
    • Privacy Policy GDPR
  • Latest News
    • The Geological Features of Pluto Have Just Gotten Dark Names Inspired from the Underworld
    • The Abuse of Imodium
    • McDonald’s Salads are worse than their Burgers
    • US Family Sues Hospital Over Botched Tonsillectomy
    • Should We Go Back to The Moon?
    • Photo of Gay Military Men Kissing Goes Viral

Pages

  • About Mirror Daily
  • Contact Us
  • Fossil Reveals That Dinosaurs Suffered from Arthritis
  • Our Team
  • Privacy Policy GDPR
  • Terms of Use
  • World Breastfeeding Week: Advantages and Disadvantages

Recent Posts

  • Using Tinder Intended for Hooking Up July 6, 2020
  • An Unbiased Enjoy of Argentine Mail Buy Brides July 1, 2020
  • Positives and negatives Of Going out with Thai Women of all ages June 27, 2020
  • Living, Death and Asian Females Looking For Guy June 27, 2020
  • The Unexposed Top secret of Japanese people Brides June 25, 2020
  • East European And Slavic Birdes-to-be ᐈ Locate Top Females For Marriage Here! June 24, 2020
  • Women Dating For the First Time June 23, 2020

Antibody-Based Therapy Against Stomach Cancer

June 6, 2016 By Melissa Gansler

human stomach

Antibody-based therapy tackles stomach cancer.

(Mirror Daily, United States) – Recent research has shown that antibody-based therapy might be efficient in helping patients with advanced stomach cancer live longer.

The phase 2 clinical trial involved 161 patients and focused on an antibody known as IMAB362. The immunotherapy was used in combination with a standard chemotherapy and extended the survival rate to 13 months compared to 8.4 months in the case of patients receiving only chemotherapy.

According to Dr. David Bernstein, chief of hepatology at Northwell Health in Manhasset, N.Y., metastatic gastric cancer is devastating, and the current effectiveness of the chemotherapeutic agents needs to be improved.

Even if the further research is needed, this study is very encouraging proving that the antibody-based therapy is effective in treating the stomach cancer. The target of the IMAB362 antibody used in this new treatment is a protein from cancer cells called claudin 18.2.

The team of German researchers learned that the patients participating in the study had the highest levels of this protein in tumors before benefiting from the immunotherapy. Furthermore, thanks to this treatment, their survival rate extended to 17 months.

The team’s research was financially supported by drug maker Ganymed Pharmaceuticals AG. and was scheduled to be shown Sunday at the annual meeting of ASCO (American Society of Clinical Oncology).

According to Dr. Salah-Eddin Al-Batran, lead researcher, and director of the Institute of Clinical Cancer Research at Nordwest Hospital in Frankfurt, claudin 18.2 is opulent in gastric tumors. Furthermore, half of all patients suffering from advanced gastric cancer might be provided soon with this antibody-based therapy.

Plus, many cancer patients are scheduled to participate in a phase 3 study starting from 2017. IMAB362 is the first antibody used to tackle claudin 18.2, found in many other cancer types as well, such as ovarian tumors, esophageal, lung and pancreatic cancer.

According to Dr. James Grendell, chief of gastroenterology, hepatology and nutrition at Winthrop-University Hospital in Mineola, N.Y., the role of the phase 3 studies will be to confirm the new findings. However, he was impressed by the new approach.

Dr. Grendell underlined that the antibody-based therapy relies on agents to deal with the barriers that prevent cancer types to be recognized and destroyed by the immune system of our body. IMAB362 is one of these agents that will expose cancer in front of the body’s self-defense mechanism.

Image Source:Vimeo

Filed Under: Health Tagged With: antibody, antibody-based therapy, Antibody-Based Therapy Against Stomach Cancer, immunotherapy, stomach cancer, therapy

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Recent Articles

Albert Einstein in group photo

Einstein’s Travel Diaries Reveal His Lesser Known Racist Side

June 14, 2018 By John Birks

Baobab tree in Tanzania

Southern Africa’s Iconic Baobab Trees Facing Massive Die-Off

June 11, 2018 By John Birks

UFO 'Self Parking' Sign

Researcher Accuses NASA of Massive Alien Cover-Up

March 5, 2018 By John Birks

Elon Musk's flying Tesla roadster

NASA Warns Elon Musk’s Flying Tesla Roadster May Contaminate Mars

February 28, 2018 By John Birks

Windows 10 home screen

Microsoft Working on Making Windows Password-Free

February 12, 2018 By John Birks

Ice Cubes

Scientists Discover Fourth State of Water: Superionic Ice

February 10, 2018 By John Birks

Head of a northern gannet

Forever Alone Nigel the Gannet Found Dead near Fake Partner

February 3, 2018 By John Birks

Globular Star Cluster

Scientists Find Surprise Black Hole in Globular Star Cluster

January 20, 2018 By John Birks

The Amazon Echo Dot

America’s Smart Speaker Market Jumps to 39 Million Users

January 15, 2018 By John Birks

Pink plasma ball

CES 2018: Intel Presents Out-of-This-World Quantum Computer

January 10, 2018 By John Birks

Teen using her iPad

Major Apple Investors Urge Company to Do More About iPhone Addiction

January 8, 2018 By John Birks

Russian spacecraft

Out-of-Control Chinese Space Station Hurling Toward Earth

January 5, 2018 By John Birks

wanning moon seen on the evening sky in between trees

Scientists Thrilled about Trump’s Initiative to Send Explorers Back to the Moon

December 31, 2017 By John Birks

Two iPhone 7 models on table

Apple Confirms Slower-iPhone Conspiracy Theory

December 22, 2017 By John Birks

Categories

  • Business & Economy
  • Capital & Retail Sector
  • Health
  • IT & Diversified Sector
  • National & Global News
  • Tech & Science

Copyright © 2021 MirrorDaily.com

About · Privacy Policy · Terms of Use · Contact

This website uses cookies to ensure you get the best experience on our website. Learn more.